Pablos-Mendez Ariel, Gowda Deepthiman K, Frieden Thomas R
College of Physicians and Surgeons, Columbia University, New York, USA.
Bull World Health Organ. 2002;80(6):489-95; discussion 495-500.
The emergence and spread of multidrug-resistant tuberculosis (MDR-TB), i.e. involving resistance to at least isoniazid and rifampicin, could threaten the control of TB globally. Controversy has emerged about the best way of confronting MDR-TB in settings with very limited resources. In 1999, the World Health Organization (WHO) created a working group on DOTS-Plus, an initiative exploring the programmatic feasibility and cost-effectiveness of treating MDR-TB in low-income and middle-income countries, in order to consider the management of MDR-TB under programme conditions. The challenges of implementation have proved more daunting than those of access to second-line drugs, the prices of which are dropping. Using data from the WHO/International Union Against Tuberculosis and Lung Disease surveillance project, we have grouped countries according to the proportion of TB patients completing treatment successfully and the level of MDR-TB among previously untreated patients. The resulting matrix provides a reasonable framework for deciding whether to use second-line drugs in a national programme. Countries in which the treatment success rate, i.e. the proportion of new patients who complete the scheduled treatment, irrespective of whether bacteriological cure is documented, is below 70% should give the highest priority to introducing or improving DOTS, the five-point TB control strategy recommended by WHO and the International Union Against Tuberculosis and Lung Disease. A poorly functioning programme can create MDR-TB much faster than it can be treated, even if unlimited resources are available. There is no single prescription for controlling MDR-TB but the various tools available should be applied wisely. Firstly, good DOTS and infection control; then appropriate use of second-line drug treatment. The interval between the two depends on the local context and resources. As funds are allocated to treat MDR-TB, human and financial resources should be increased to expand DOTS worldwide.
耐多药结核病(MDR-TB)的出现和传播,即对至少异烟肼和利福平耐药,可能会威胁到全球结核病的控制。在资源非常有限的情况下,如何应对耐多药结核病的最佳方式引发了争议。1999年,世界卫生组织(WHO)成立了一个关于强化直接观察治疗(DOTS-Plus)的工作组,这是一项探索在低收入和中等收入国家治疗耐多药结核病的项目可行性和成本效益的倡议,以便在项目条件下考虑耐多药结核病的管理。事实证明,实施的挑战比获取二线药物的挑战更为艰巨,而二线药物的价格正在下降。利用WHO/国际防痨和肺部疾病联盟监测项目的数据,我们根据结核病患者成功完成治疗的比例以及既往未治疗患者中的耐多药结核病水平对各国进行了分组。由此产生的矩阵为决定是否在国家项目中使用二线药物提供了一个合理的框架。治疗成功率(即完成预定治疗的新患者比例,无论是否有细菌学治愈记录)低于70%的国家应将引入或改进DOTS(WHO和国际防痨和肺部疾病联盟推荐的五点结核病控制策略)作为最高优先事项。一个运作不佳的项目产生耐多药结核病的速度可能比治疗它的速度快得多,即使有无限的资源也是如此。控制耐多药结核病没有单一的处方,但应明智地应用各种可用工具。首先,做好DOTS和感染控制;然后适当使用二线药物治疗。两者之间的间隔取决于当地情况和资源。在分配资金治疗耐多药结核病时,应增加人力和财力资源,以在全球范围内扩大DOTS。